None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged 19 to 65 years 2. Patients with American Society of Anesthesiologists (ASA) physical status I or II 3.Male and female patients scheduled for nasal surgery under general anesthesia
Exclusion criteria
Exclusion criteria: 1. Patients with a body mass index (BMI) = 30 kg/m² 2. Patients with a history or anticipation of a difficult airway 3. Patients with obstructive sleep apnea 4. Patients with recent respiratory infection, chronic respiratory disease, or chronic cough 5. Current smokers 6 Patients currently taking opioids, sedatives, antitussives, or angiotensin-converting enzyme (ACE) inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective effect-site concentration (EC50) of remifentanil for cough suppression | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery times; Time to eye opening and Time to extubation, ;Hemodynamic change( heart rate, blood pressure, saturation);Postanesthetic Complication (sedation, bradypnea and desaturation, nausea and vomitting) | — |
Countries
Korea, Republic of
Contacts
The Catholic University of Korea, St. Vincent's Hospital